Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MEMEI Pharma, Inc. logo

MEI Pharma, Inc. (MEIP)

NASDAQ Capital Market · Currency in USD
$3.07 ▲ +0.29 (+10.43%)
At close: Sep 10, 4:00 PM ET. Market closed.
$3.20 ▲ +0.13 (+4.23%)
After hours: Sep 10, 7:58 PM ET

Summary

Previous Close
$2.78
Open
$2.89
Day's Range
$2.85 – $3.25
52 Week Range
$1.46 – $9.00
Volume
3,967,419
Avg. Volume
1,533,477
Market Cap
$20.45M
Beta (5Y Monthly)
0.22
PE Ratio (TTM)
--
EPS (TTM)
-$1.70
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
Nov 16, 2023
1y Target Est
--

Profile: MEI Pharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
28
CEO
Justin J. File CPA

MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies. Additionally, Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is undergoing Phase Ib clinical trials for acute myeloid leukemia and other B-cell malignancies.

Earnings

DateEst.Actual
Feb 19, 2026–-$0.82
Nov 10, 2025–-$0.12
Sep 18, 2025–-$1.13
May 13, 2025–-$0.39
Feb 12, 2025-$2.20-$0.48Beat
Nov 12, 2024-$1.70-$1.20Beat

Analyst view

Rating: Buy
Buy 56% · Hold 39% · Sell 6%

Get free alerts on MEIP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.